Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...

Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...

Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 2:00 PM ETCompany ParticipantsJames Patrick Kelly ...

The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple ...

The RSV shot, mRESVIA, secured U.S. approval on Thursday for expanded use in at-risk adults aged 18 to 59 years, but needs ...

WASHINGTON >> U.S. Health Secretary Robert Kennedy Jr. named eight members to serve on a key panel of vaccine advisers on ...